{
    "id": "34a462e8-0259-6d63-e063-6294a90a846f",
    "indications": {
        "text": "duloxetine delayed-release capsules indicated treatment : major depressive disorder adults generalized anxiety disorder adults pediatric patients 7 years age older diabetic peripheral neuropathic pain adults fibromyalgia adults pediatric patients 13 years age older chronic musculoskeletal pain adults",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic musculoskeletal pain",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_120188"
            }
        ]
    },
    "contraindications": {
        "text": "take duloxetine delayed-release capsules daily , without food . swallow whole ; crush , chew , open capsule ( 2.1 ) indication starting dose target dose maximum dose mdd ( 2.2 ) 40 mg/day 60 mg/day acute treatment : 40 mg/day ( 20 mg twice daily ) 60 mg/day ( daily 30 mg twice daily ) ; maintenance treatment : 60 mg/day 120 mg/day gad ( 2.3 ) adults 60 mg/day 60 mg/day ( daily ) 120 mg/day geriatric 30 mg/day 60 mg/day ( daily ) 120 mg/day pediatrics ( 7 years 17 years age ) 30 mg/day 30 60 mg/day ( daily ) 120 mg/day dpnp ( 2.4 ) 60 mg/day 60 mg/day ( daily ) 60 mg/day fm ( 2.5 ) adults pediatrics ( 13 years 17 years age ) 30 mg/day 60 mg/day ( daily ) 60 mg/day chronic musculoskeletal pain ( 2.6 ) 30 mg/day 60 mg/day ( daily ) 60 mg/day discontinuing duloxetine delayed-release capsules : gradually reduce avoid discontinuation symptoms ( 2.8 , 5.7 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "chronic musculoskeletal pain",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_120188"
            }
        ]
    },
    "warningsAndPrecautions": "duloxetine delayed-release capsules available following strengths , colors , imprints , presentations : body color white , cap color blue , cap imprint ap , body imprint dlx60 equivalent duloxetine base ndc : 70518-1011-00 ndc : 70518-1011-01 ndc : 70518-1011-02 packaging : 30 1 blister pack packaging : 30 1 bottle , plastic packaging : 60 1 bottle , plastic store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "maois intended treat psychiatric disorders duloxetine within 5 days stopping treatment duloxetine contraindicated increased risk serotonin syndrome . duloxetine within 14 days stopping maoi intended treat psychiatric disorders contraindicated [ ( 2.8 ) ( 5.4 ) ] . starting duloxetine patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.9 ) ( 5.4 ) ] .",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "DULOXETINE HYDROCHLORIDE",
            "code": "9044SC542W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_36808"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "Duloxetine",
    "effectiveTime": "20250508",
    "indications_original": "Duloxetine delayed-release capsules are indicated for the treatment of:\n                  \n                     Major depressive disorder in adults\n                     Generalized anxiety disorder in adults and pediatric patients 7 years of age and older\n                     Diabetic peripheral neuropathic pain in adults\n                     Fibromyalgia in adults and pediatric patients 13 years of age and older\n                     Chronic musculoskeletal pain in adults",
    "contraindications_original": "Take duloxetine delayed-release capsules once daily, with or without food. Swallow whole; do not crush, or chew,\u00a0or open capsule ( 2.1 ) Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 40 mg/day to 60 mg/day Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 120 mg/day GAD ( 2.3 ) Adults 60 mg/day 60 mg/day (once daily) 120 mg/day Geriatric 30 mg/day 60 mg/day (once daily) 120 mg/day Pediatrics (7 years\u00a0to 17 years of age) 30 mg/day 30 to 60 mg/day (once daily) 120 mg/day DPNP ( 2.4 ) 60 mg/day 60 mg/day (once daily) 60 mg/day FM ( 2.5 ) Adults and Pediatrics (13 years to 17 years of age) 30 mg/day 60 mg/day (once daily) 60 mg/day Chronic Musculoskeletal Pain ( 2.6 ) 30 mg/day 60 mg/day (once daily) 60 mg/day Discontinuing duloxetine delayed-release capsules: Gradually reduce dosage to avoid discontinuation symptoms ( 2.8 , 5.7 )",
    "warningsAndPrecautions_original": "Duloxetine delayed-release capsules are available in the following strengths, colors, imprints, and presentations:\n                  Body color White, Cap color Blue, Cap imprint ap, Body imprint DLX60\n                  equivalent to duloxetine base\n                  NDC: 70518-1011-00\n                  NDC: 70518-1011-01\n                  NDC: 70518-1011-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOTTLE, PLASTIC\n                  PACKAGING: 60 in 1 BOTTLE, PLASTIC\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see\u00a0USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "The use of MAOIs intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. The use of duloxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders is contraindicated\n \n  [see Dosage and Administration (\n  \n   2.8) and Warnings and Precautions (\n  \n   5.4)].\n \n  \n                  \n                  \n                  Starting duloxetine in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome\n \n  [see Dosage and Administration (\n  \n   2.9) and Warnings and Precautions (\n  \n   5.4)].",
    "drug": [
        {
            "name": "Duloxetine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_36796"
        }
    ]
}